Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.38 |
| ▸ | OPA1 | O60313 | 1/20 | 0.35 |
| ▸ | EIF5B | O60841 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17270075 | 0.89 | HTR2A (0.43) | EGFRHTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL17270039 | 0.88 | HTR2A (0.44) | EGFRHTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL17270038 | 0.88 | HTR2A (0.42) | EGFRHTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL17261896 | 0.88 | HTR2A (0.42) | EGFRHTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL18958991 | 0.87 | HTR2A (0.41) | EGFRHTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL17261870 | 0.86 | HTR2A (0.46) | EGFRHTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL17269954 | 0.85 | HTR2A (0.45) | EGFRHTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL18958986 | 0.85 | EGFR (0.45) | EGFRHTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL18958987 | 0.85 | EGFR (0.47) | EGFRHTR2AHTR2C | |
| SCHEMBL17261887 | 0.85 | EGFR (0.40) | EGFRHTR2AHTR2CMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885HTR2A 1220/4885HTR2C 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.